Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain
Status:
Withdrawn
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is an open label study of up to approximately 52 weeks duration to assess the safety and
effectiveness of BEMA Buprenorphine in the management of moderate to severe chronic low back
pain.
BEMA Buprenorphine is an oral transmucosal form of the opioid analgesic, buprenorphine
hydrochloride, intended for application to the buccal mucosa. Buprenorphine is a synthetic
opioid that is classified as a partial μ-receptor agonist and a Schedule III controlled
substance in the United States.